HomeCompareARSEF vs JNJ

ARSEF vs JNJ: Dividend Comparison 2026

ARSEF yields 738.31% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARSEF wins by $1414259.51M in total portfolio value
10 years
ARSEF
ARSEF
● Live price
738.31%
Share price
$0.01
Annual div
$0.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1414259.54M
Annual income
$1,116,720,852,249.49
Full ARSEF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — ARSEF vs JNJ

📍 ARSEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARSEFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARSEF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARSEF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARSEF
Annual income on $10K today (after 15% tax)
$62,756.38/yr
After 10yr DRIP, annual income (after tax)
$949,212,724,412.07/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, ARSEF beats the other by $949,212,720,374.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARSEF + JNJ for your $10,000?

ARSEF: 50%JNJ: 50%
100% JNJ50/50100% ARSEF
Portfolio after 10yr
$707129.79M
Annual income
$558,360,428,499.68/yr
Blended yield
78.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ARSEF
No analyst data
Altman Z
-11.3
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARSEF buys
0
JNJ buys
0
No recent congressional trades found for ARSEF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARSEFJNJ
Forward yield738.31%2.14%
Annual dividend / share$0.04$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1414259.54M$30.5K
Annual income after 10y$1,116,720,852,249.49$4,749.88
Total dividends collected$1390401.07M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ARSEF vs JNJ ($10,000, DRIP)

YearARSEF PortfolioARSEF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$84,531$73,831.03$10,594$274.49+$73.9KARSEF
2$673,721$583,272.31$11,294$360.69+$662.4KARSEF
3$5,065,495$4,344,613.74$12,133$476.91+$5.05MARSEF
4$35,948,862$30,528,782.55$13,156$635.42+$35.94MARSEF
5$240,948,479$202,483,196.52$14,432$854.61+$240.93MARSEF
6$1,526,179,885$1,268,365,013.02$16,056$1,162.76+$1526.16MARSEF
7$9,141,319,322$7,508,306,845.17$18,175$1,604.53+$9141.30MARSEF
8$51,811,405,197$42,030,193,522.31$21,009$2,252.68+$51811.38MARSEF
9$278,073,543,585$222,635,340,024.33$24,911$3,229.73+$278073.52MARSEF
10$1,414,259,543,886$1,116,720,852,249.49$30,458$4,749.88+$1414259.51MARSEF

ARSEF vs JNJ: Complete Analysis 2026

ARSEFStock

Altai Resources Inc. operates as a natural resource exploration and development company in Canada. The company explores for oil and gas, and gold properties. It holds a 100% interest in the Sorel-Trois Rivieres natural gas property comprising five oil and gas and reservoir licenses covering an area of 68,483 hectares located in St. Lawrence Lowlands, Quebec; a 45% interest in the Cessford oil property covering an area of 240 acres located in the Cessford area of Southern Alberta; and a 50% interest in the Malartic gold property which consists of six map designated claims covering an area of 127.6 hectares located in Quebec. Altai Resources Inc. was incorporated in 1955 and is headquartered in Toronto, Canada.

Full ARSEF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ARSEF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARSEF vs SCHDARSEF vs JEPIARSEF vs OARSEF vs KOARSEF vs MAINARSEF vs ABBVARSEF vs MRKARSEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.